

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries

New/Noteworthy E-Utilities

LinkOut Cubby

Related Resources **Order Documents NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov **PubMed Central** 

Privacy Policy

decreases human pancreatic carcinoma growth.

Liu CD, Rongione AJ, Garvey L, Balasubramaniam A, McFadden DW.

Department of Surgery, UCLA Center for Health Sciences, USA.

BACKGROUND: Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY). We examined whethe adjuvant treatment with PYY or its synthetic analog, BIM-43004, would decrease human pancreatic adenocarcinoma growth. MATERIALS AND METHODS: Human pancreatic ductal adenocarcinomas, MiaPaCa-2 and BxPC-3, were cultured and assessed for growth by MTT assay. Pancreatic cancer cells received 500 pmol of PYY or BIM-43004 for 24 hours prior to 5 fluorouracil (5-FU; 10 micrograms/mL) and leucovorin (40 micrograms/mL) administration. Cell membrane epidermal growth factor (EGF) receptors wer analyzed by Western blotting after exposure to peptides and chemotherapy. RESULTS: Cancer cell growth was reduced in all groups receiving hormona pretreatment (23% PYY/5-FU/leucovorin versus control; 27% BIM-43004/5-FU/leucovorin versus control) as compared with groups receiving 5-FU and leucovorin only (16% versus control). The EGF receptor expression was reduced by 30% in cells treated with PYY/5-FU/leucovorin and by 45% in cells treated with BIM/5-FU/leucovorin as compared with control cells without treatment. CONCLUSION: Human pancreatic cancer cell growth is further decreased when pretreated with PYY or its synthetic analog prior to chemotherapy.

PMID: 8554139 [PubMed - indexed for MEDLINE]

			V
Display	Abstract	Show: 20 ▼ Sort ▼	Send to Text

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Exhibit 2